Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Chinese RCT (n=571) found those given sintilimab, a PD-1 inhibitor, plus a bevacizumab biosimilar (IBI305), had a significantly longer progression free survival than those given sorafenib (4.6 vs 2.8 months, HR 0.56, 95%CI 0.46-0.70), with an acceptable safety profile.

SPS commentary:

Currently sintilimab injection is approved in China in combination with pemetrexed and platinum chemotherapy as first-line therapy for the treatment of non-squamous NSCLC.

The Lancet Oncology